NCT02544997: A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway

NCT02544997
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: AR+, ER++, PR+
Other Mutations: EGFR, HER2+, HER2+-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have an activated HER2+ mutation or EGFR mutation/gene amplification or activated AR pathway
Exclusions: No prior history of pan-HER+ TKI including poziotinib for MBC; Documented leptomeningeal brain metastasis; Known brain metastases unless treated and stable; Patients with HER2++ breast cancer
https://ClinicalTrials.gov/show/NCT02544997

Comments are closed.

Up ↑